Preskoči na sadržaj
Digitalni repozitorijum Stomatološkog fakulteta u Pančevu

Pun zapis

dc:titleConcomitant mitral valve repair and resynchronization therapy
dc:creatorBorovic, S.
dc:creatorRistic, V.
dc:creatorAngelkov, L.
dc:creatorVukajlovic, Z.
dc:creatorDabić, Petar
dc:creatorDjukanovic, B.
dc:subjectmitral valve repair
dc:subjectcardiac resynchronization therapy
dc:subjectfunctional mitral regurgitation
dc:subjectcombined surgery
dc:subjectleft ventricular remodeling
dc:subjectend-systolic volume
dc:subject6-minute walk test
dc:subjectpostoperative outcomes
dc:subjectechocardiographic response
dc:descriptionFunctional mitral regurgitation (MR) affects 90% of cardiac resynchronization therapy (CRT) candidates, with moderate–severe/severe MR being present in 35%. The purpose was to assess the outcome of CRT candidates with severe MR undergoing concomitant mitral valve repair and resynchronization therapy. A case series of 3 consecutive patients underwent concomitant mitral valve repair and resynchronization therapy between September 2011 and January 2012 at our institution. Prospectively recorded preoperative, intraoperative, and postoperative data were retrospectively screened for in-hospital mortality, adverse postoperative events and functional and echocardiographic changes. Patients were reevaluated at 6 and 12 months. There was no in-hospital mortality and major adverse postoperative events. End-systolic LV volumes decreased by >20% compared with baseline at 6-month and 12-month follow-up in first and second patient. Third patient was not considered echocardiographic responder (no reduction in LV volume). First and second patient improved >10% the distance covered in the 6-minute walking test at follow-up. Positive clinical response was absent in third patient. At 6-month and 12-month MR was 2 and 3+ respectively in third patient. No MR recurrence was observed in remaining patients. CRT in patients with no residual MR yields improved reverse remodeling, response to resynchronization, functional status and survival (clinical and ECHO responders). Concomitant mitral valve repair and resynchronization therapy is feasible, safe, with acceptable results.
dc:publisherBioMed Central
dc:date2013
dc:typeinfo:eu-repo/semantics/article
dc:typeinfo:eu-repo/semantics/publishedVersion
dc:identifierhttps://stomatoloskifakultet.rs/nauka/publikacija/958
dc:identifierDOI 10.1186/1749-8090-8-S1-O271
dc:identifierISSN 1749-8090
dc:sourceJournal of Cardiothoracic Surgery 8(S1): 271
dc:languageen
dc:rightsinfo:eu-repo/semantics/closedAccess
dc:rightsSva prava zadržana